SCHEMBL24316290

SCHEMBL24316290

CC(C)C(=O)N(C)C(C)c1ccccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.46
CYP3A4 P08684 3/20 0.46
CYP1A2 P05177 2/20 0.46
POLB P06746 1/20 0.46
TSHR P16473 3/20 0.45
CYP2C19 P33261 2/20 0.43
KDM4E B2RXH2 3/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 3/20 0.43
LMNA P02545 2/20 0.43
ABCB11 O95342 1/20 0.43
ESR1 P03372 1/20 0.43
ADRA2A P08913 1/20 0.43
CYP2C9 P11712 1/20 0.43
PDE4A P27815 1/20 0.43
ADRA1A P35348 1/20 0.43
OPRK1 P41145 1/20 0.43
STAT6 P42226 1/20 0.43
SLC6A3 Q01959 1/20 0.43
HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26620700 0.85 CYP3A4 (0.47) RAB9ACYP3A4CYP1A2POLBTSHR
SCHEMBL24316289 0.81 CYP2C19 (0.46) RAB9ACYP3A4CYP1A2TSHRCYP2C19
SCHEMBL11613461 0.78 NPSR1 (0.46) RAB9ACYP3A4CYP1A2POLBTSHR
Hydrochloric Acid SCHEMBL11613384 0.77 NPSR1 (0.44) RAB9ACYP3A4CYP1A2POLBTSHR
SCHEMBL9059100 0.77 TSHR (0.45) RAB9ACYP3A4CYP1A2POLBTSHR
SCHEMBL9382802 0.77 TSHR (0.45) RAB9ACYP3A4CYP1A2POLBTSHR
SCHEMBL6226578 0.76 TSHR (0.55) CYP3A4CYP1A2TSHRCYP2C19KDM4E
SCHEMBL347926 0.74 TSHR (0.52) CYP3A4CYP1A2TSHRSLC6A3KCNA5
SCHEMBL888725 0.73 CYP3A4 (0.46) RAB9ACYP3A4CYP1A2POLBTSHR
SCHEMBL11628590 0.73 RAB9A (0.48) RAB9ACYP3A4CYP1A2POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081925-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed
US-9585884-B2 Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 AUSPEX PHARMACEUTICALS, INC. (US) 2017-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 RAB9A 3592/4885CYP3A4 2566/4885CYP1A2 2070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.